Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2026-05-19 08:11:07 ET · period of report 2026-05-18 · accession 0001193125-26-229727 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-19 08:11 | 2026-05-18 | ARTV | Miralles Gines Diego | Pres, Head of R, D | A - Grant | $0.00 | +77.5K | 77.5K | New | $0 |
| D | 2026-05-19 08:11 | 2026-05-18 | ARTV | Miralles Gines Diego | Pres, Head of R, D | A - Grant | $0.00 | +232.5K | 232.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-18 | A | A | 77,500 | $0.00 | 77,500 | D | — | — | (F1) Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2026-05-18 | A | A | 232,500 | $0.00 | 232,500 | D | $9.22 · — to 2036-05-17 | 232,500 Common Stock | (F2) Represents stock option award granted under the Issuer's 2025 Inducement Plan. (F3) 25% of the shares initially subject to the option will vest and become exercisable on May 15, 2027, and the balance of the shares subject to the option shall vest and become exercisable at a rate of 1/36th per month over the following 36 months. |